STEAP3 and neoplasm: Liu et al. (2021) identified that STEAP3 knockdown blocked erastin or RSL3-induced ferroptosis. Accumulating evidence has implicated that ferroptosis participates in the development of diverse cancer types and affects the response to therapies (Chen et al., 2021b; Qu, Peng & Liu, 2022). Mesenchymal and dedifferentiated tumor cells, associated with resistance to common therapeutics, are susceptible to ferroptosis inducers (Tsoi et al., 2018; Viswanathan et al., 2017).